Risperidone Reduces Matrix Metalloproteinase-9 and Increases Neurotrophin-3 in Schizophrenia Spectrum of Disorder.

Even though earlier studies have reported alteration in the markers of synaptic plasticity (Matrix metalloproteinase-9 [MMP-9] and Neurotrophin-3 [NT-3]), there are no reports about the effect of risperidone on the same. The present study was designed to assess the effect of risperidone on NT-3 and MMP-9 levels in patients with schizophrenia spectrum of disorder and to investigate whether these markers can be used to predict the treatment response in these patients. 62 schizophrenia spectrum of disorder patients were enrolled in the study and were treated with 4 mg of risperidone OD. Serum NT-3 and MMP-9 levels were compared at baseline and after 6 weeks following risperidone treatment. Severity of the disease was assessed using Positive and Negative Syndrome Scale (PANSS). MMP-9 was significantly reduced and NT-3 was significantly increased in schizophrenia spectrum of disorder after treatment with risperidone. We also found a significant reduction in MMP-9 levels in the non-responders group. At a cut off of 1225 ng/mL, MMP-9 can predict response to treatment with 64% sensitivity and 62% specificity and at a cut off of 957 pg/mL, NT-3 predicted the response to treatment with 60% sensitivity and 62% specificity. We conclude that risperidone decreases the serum levels of MMP-9 and increases the NT-3 levels in schizophrenia spectrum of disorder. MMP-9 and NT-3 can predict the response to treatment with risperidone.